HK1180252A1 - 抗凝劑的溶出改善方法 - Google Patents

抗凝劑的溶出改善方法

Info

Publication number
HK1180252A1
HK1180252A1 HK13107729.8A HK13107729A HK1180252A1 HK 1180252 A1 HK1180252 A1 HK 1180252A1 HK 13107729 A HK13107729 A HK 13107729A HK 1180252 A1 HK1180252 A1 HK 1180252A1
Authority
HK
Hong Kong
Prior art keywords
anticoagulant
dissolvability
improving
improving dissolvability
Prior art date
Application number
HK13107729.8A
Other languages
English (en)
Inventor
Makoto Kamada
Gaku Sekiguchi
Motonori Kidokoro
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44649152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1180252(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of HK1180252A1 publication Critical patent/HK1180252A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
HK13107729.8A 2010-03-19 2013-07-02 抗凝劑的溶出改善方法 HK1180252A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010063694 2010-03-19
PCT/JP2011/055956 WO2011115067A1 (ja) 2010-03-19 2011-03-14 抗凝固剤の溶出改善方法

Publications (1)

Publication Number Publication Date
HK1180252A1 true HK1180252A1 (zh) 2013-10-18

Family

ID=44649152

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13107729.8A HK1180252A1 (zh) 2010-03-19 2013-07-02 抗凝劑的溶出改善方法

Country Status (13)

Country Link
US (1) US9918975B2 (zh)
EP (1) EP2548556B1 (zh)
JP (1) JP5390014B2 (zh)
KR (1) KR101792299B1 (zh)
CN (1) CN102791271B (zh)
BR (1) BR112012023654B1 (zh)
CA (1) CA2793525C (zh)
ES (1) ES2601884T3 (zh)
HK (1) HK1180252A1 (zh)
HU (1) HUE031059T2 (zh)
IL (1) IL221946A (zh)
TW (1) TWI496787B (zh)
WO (1) WO2011115067A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5749247B2 (ja) 2010-02-22 2015-07-15 第一三共株式会社 経口用徐放性固形製剤
WO2011115067A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 抗凝固剤の溶出改善方法
KR101940840B1 (ko) 2011-08-10 2019-01-21 다이이찌 산쿄 가부시키가이샤 디아민 유도체 함유 의약 조성물
EP3177290B1 (en) * 2014-08-06 2018-06-20 Sandoz AG Pharmaceutical compositions of edoxaban
CN106913529B (zh) * 2015-12-24 2020-12-04 江苏恒瑞医药股份有限公司 一种来那替尼或其可药用盐药物组合物的制备方法
TWI826474B (zh) 2018-06-27 2023-12-21 日商第一三共股份有限公司 包含二胺衍生物之顆粒劑、以及其用途及製造方法
KR102222774B1 (ko) * 2018-07-27 2021-03-04 보령제약 주식회사 에독사반을 포함하는 약학적 제제 및 이의 제조방법
KR20200079957A (ko) 2018-12-26 2020-07-06 한국콜마주식회사 에독사반을 함유한 경구용 의약 조성물 및 그의 제조방법
EP3744320A1 (en) 2019-05-29 2020-12-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising edoxaban
EP3838267A1 (en) 2019-12-19 2021-06-23 Biohorm, S.L. Edoxaban tablets
WO2022129535A1 (en) 2020-12-18 2022-06-23 Krka, D.D., Novo Mesto Edoxaban formulation containing no sugar alcohols

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
US4582570A (en) 1981-07-24 1986-04-15 Merix Corporation Azeotropic dehydration distillation process
JP2814513B2 (ja) 1988-02-03 1998-10-22 吉富製薬株式会社 溶出性の改良された製剤組成物
WO1989006959A1 (en) 1988-02-03 1989-08-10 Yoshitomi Pharmaceutical Industries, Ltd. Pharmaceutical composition having improved releasability
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5055600A (en) 1990-04-24 1991-10-08 Rockwell International Corporation Glycidyl azide polymer (gap) synthesis by molten salt method
JPH0873345A (ja) 1994-09-05 1996-03-19 Terumo Corp 医薬製剤
US5677469A (en) 1995-05-18 1997-10-14 Sepracor, Inc. Process for resolving chiral acids with 1-aminoindan-2-ols
JPH09165346A (ja) * 1995-12-18 1997-06-24 Sanei Gen F F I Inc 錠 剤
JPH09309829A (ja) 1996-05-22 1997-12-02 Taiyo Yakuhin Kogyo Kk ニトレンジピン含有経口投与製剤およびその製造法
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
DE69730982T2 (de) * 1996-10-28 2005-09-01 General Mills, Inc., Minneapolis Einbettung und einkapselung von teilchen zur kontrollierten abgabe
EP0839526A3 (en) 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
JP4044709B2 (ja) 1999-11-19 2008-02-06 信越化学工業株式会社 水系フィルムコーティング剤及び経口固形製剤
TWI288745B (en) 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US20030086972A1 (en) 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
CA2426263C (en) 2000-10-24 2010-05-25 Ajinomoto Co., Inc. Nateglinide-containing preparation
US20020160048A1 (en) 2001-02-15 2002-10-31 Karoline Bechtold-Peters Medical formulation containing a muscarinic agonist
DE10106971A1 (de) 2001-02-15 2002-08-29 Boehringer Ingelheim Pharma Arzneimittelformulierung die einen muskarinischen Agonisten enthält
US6761905B2 (en) * 2001-05-01 2004-07-13 Wei Ming Pharmaceutical Mfg. Co., Ltd. Process for the preparation of direct tabletting formulations and aids
EP1405852B9 (en) 2001-06-20 2013-03-27 Daiichi Sankyo Company, Limited Diamine derivatives
KR100908418B1 (ko) 2001-06-20 2009-07-21 액티버스 파마 컴퍼니 리미티드 퀴놀리논 유도체 의약 조성물 및 그의 제조 방법
WO2003000657A1 (fr) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
JP3939601B2 (ja) 2001-06-20 2007-07-04 株式会社アクティバスファーマ キノリノン誘導体医薬組成物及びその製造方法
IL160204A0 (en) 2001-08-09 2004-07-25 Daiichi Seiyaku Co Diamine derivatives
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TW200306868A (en) 2002-05-22 2003-12-01 Shionogi & Co Composition of hardly soluble medicine with improved solubility
CA2511493A1 (en) 2002-12-25 2004-07-15 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
FR2854073B1 (fr) 2003-04-08 2008-03-14 Novartis Ag Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre
JP4606258B2 (ja) 2003-06-17 2011-01-05 協和発酵キリン株式会社 塩酸ベニジピン含有医薬組成物
JP3786287B2 (ja) 2003-06-17 2006-06-14 協和醗酵工業株式会社 塩酸ベニジピン含有医薬組成物
KR101215153B1 (ko) 2003-11-12 2012-12-24 다이이찌 산쿄 가부시키가이샤 티아졸 유도체의 제조법
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US8686189B2 (en) 2005-09-16 2014-04-01 Daiichi Sankyo Company, Limited Optically active diamine derivative and process for producing the same
EP2090300A4 (en) 2006-11-30 2010-02-10 Takeda Pharmaceutical PREPARATION WITH EXTENDED RELEASE
NZ579725A (en) * 2007-03-29 2012-02-24 Daiichi Sankyo Co Ltd Tablet composition having improved dissolution property
TW200909437A (en) 2007-06-21 2009-03-01 Daiichi Sankyo Co Ltd Process for the preparation of diamine-derivatives
TW201014850A (en) 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
TW201102064A (en) 2009-06-18 2011-01-16 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved dissolution property
WO2011102506A1 (ja) 2010-02-22 2011-08-25 第一三共株式会社 経口用徐放性固形製剤
WO2011102505A1 (ja) 2010-02-22 2011-08-25 第一三共株式会社 経口用徐放性固形製剤
JP5749247B2 (ja) 2010-02-22 2015-07-15 第一三共株式会社 経口用徐放性固形製剤
WO2011115067A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 抗凝固剤の溶出改善方法
CN102058889A (zh) 2010-11-05 2011-05-18 王定豪 包含抗凝血类药物的分散片及其应用
KR101940840B1 (ko) 2011-08-10 2019-01-21 다이이찌 산쿄 가부시키가이샤 디아민 유도체 함유 의약 조성물

Also Published As

Publication number Publication date
HUE031059T2 (en) 2017-06-28
CN102791271B (zh) 2014-05-14
ES2601884T3 (es) 2017-02-16
BR112012023654B1 (pt) 2022-04-12
EP2548556A1 (en) 2013-01-23
TWI496787B (zh) 2015-08-21
EP2548556A4 (en) 2014-07-16
TW201139452A (en) 2011-11-16
CA2793525A1 (en) 2011-09-22
US9918975B2 (en) 2018-03-20
JPWO2011115067A1 (ja) 2013-06-27
KR101792299B1 (ko) 2017-10-31
IL221946A (en) 2017-03-30
CN102791271A (zh) 2012-11-21
KR20130016224A (ko) 2013-02-14
BR112012023654A2 (pt) 2020-11-24
EP2548556B1 (en) 2016-08-10
US20130022683A1 (en) 2013-01-24
JP5390014B2 (ja) 2014-01-15
WO2011115067A1 (ja) 2011-09-22
CA2793525C (en) 2014-05-06

Similar Documents

Publication Publication Date Title
HK1180252A1 (zh) 抗凝劑的溶出改善方法
EP2552873A4 (en) PREPARATION FOR HEXAFLUOR-2-BUTEN
GB201001833D0 (en) Method
EP2591130A4 (en) METHOD FOR THE ECONOMIC EXTRACTION OF LITHIUM FROM A SOLUTION WITH LITHIUM
EP2938529A4 (en) Method of removing suspected section of track
GB201007353D0 (en) Method
HU1000330D0 (en) Novel method
HK1183864A1 (zh) 生產喹啉- -羧酰胺的方法
EP2628153A4 (en) METHOD FOR ESTABLISHING LINGUISTIC PROFILE
GB201007354D0 (en) Method
GB201011513D0 (en) Method
PL2718330T3 (pl) Proces ekstrakcji pektyny
EP2771442A4 (en) LIPID EXTRACTION PROCESS
GB201004759D0 (en) Method
GB201008900D0 (en) Method of machining
GB201012148D0 (en) Method
GB201007454D0 (en) Method of determining tolerance
GB201010855D0 (en) Method
GB201006306D0 (en) Method
EP2780475A4 (en) PROCESS FOR ALL-PECIFIC AMPLIFICATION
PL2526087T3 (pl) Sposób wytwarzania wodoronadtlenku alkilu
GB201012784D0 (en) Method
GB201007207D0 (en) Method
PL2380963T3 (pl) Sposób perfumowania
GB201017003D0 (en) Method